STOCKS TELEGRAPH

Tag: Cidara

  • Cidara Therapeutics (CDTX) Shares Surge In Pre-Market Trading

    Cidara Therapeutics (CDTX) Shares Surge In Pre-Market Trading

    As of the last check, shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) had risen 81.11% to $38.07 after a robust pre-market rally. Following the release of favorable topline data from its Phase 2b NAVIGATE research, which evaluated the effectiveness of CD388—an investigational antiviral—in preventing seasonal influenza in healthy, unvaccinated individuals aged 18 to 64, CDTX announced the noteworthy rise.

    Primary and Secondary Endpoints Are Reached by the Trial

    All three dosing groups showed statistically significant preventive efficacy (PE), achieving the primary objective of the randomized, double-blind, placebo-controlled study. Before the flu season, participants received a single dose of CD388 and were monitored for influenza for 24 weeks following laboratory and clinical confirmation.

    Notably, the experiment also achieved all secondary objectives, including sustaining PE for up to 28 weeks and demonstrating efficacy at 37.8°C and 37.2°C temperature thresholds.

    Clinical Potential is Reinforced by the Safety Profile

    There were no dose-limiting or unexpected treatment-emergent adverse effects, and CD388 was well tolerated at all tested dosages. There were no notable safety signals or major adverse events linked to the medicine, according to safety statistics that were consistent between the treatment and placebo groups. Additionally, all CD388 and placebo groups had comparable rates of injection site responses, confirming the medication’s good safety record.

    Prospects for Strategy and the Future of Regulation

    Regardless of a patient’s immunological condition, Cidara has stated that it is certain that CD388 will provide comprehensive, once-per-season protection against influenza A and B strains. For high-risk groups including those with chronic illnesses and immunocompromised persons, CDTX sees these discoveries as a possible breakthrough in the prevention of seasonal influenza.

    Cidara has requested an end-of-Phase 2 meeting with the U.S. FDA to discuss the design and scheduling of a Phase 3 study, and it intends to disclose further NAVIGATE trial findings at scientific conferences in 2025. CD388 is positioned as a strong contender to revolutionize seasonal influenza prevention thanks to encouraging Phase 2b findings and a well-defined regulatory route.

  • Cidara Therapeutics (CDTX) Stock Surge After-Hours On Strategic Divestment

    Cidara Therapeutics (CDTX) Stock Surge After-Hours On Strategic Divestment

    Cidara Therapeutics (NASDAQ: CDTX) shares experienced a remarkable surge subsequent to the company’s announcement regarding the transfer of rezafungin, an antifungal therapeutic, to its collaborator, Mundipharma. Cidara Therapeutics shares value soared by an impressive 40.68% to $17.29 during after-hours trading.

    The surge followed a substantial increase in CDTX stock on the US charts of 19.90% to $12.29 in the regular trading session. As per the terms delineated in the agreement, Mundipharma will procure rezafungin for an undisclosed monetary consideration. The procurement encompasses assuming responsibility for ongoing expenditures linked with the ReSPECT Phase 3 clinical trial, the patent portfolio associated with rezafungin, and the manufacturing and regulatory obligations.

    This deal is projected to translate into significant cost savings of approximately $128 million for Cidara Therapeutics over the lifespan of the rezafungin patents. This translates to a cost avoidance of $67 million in clinical development and an estimated $61 million in other potential liabilities. This financial windfall will empower Cidara Therapeutics to channel its resources towards its promising Cloudbreak pipeline.

    This pipeline holds immense potential, harboring the possibility of groundbreaking new therapies in the fields of oncology and other disease areas.  Following the acquisition, Mundipharma will assume ownership of all future royalties and milestones associated with rezafungin.  The agreement also entails the transfer of all intellectual property rights, product data, regulatory approvals, and inventory pertaining to rezafungin.

    It’s worth noting that Mundipharma had already settled a $2.786 million milestone payment to Cidara, triggered by the UK regulatory body’s approval of rezafungin acetate for treating invasive candidiasis in adults. Furthermore, Mundipharma has agreed to waive a $11.145 million debt owed by Cidara upon successful completion of the asset transfer process.

    By divesting rezafungin, Cidara Therapeutics has secured substantial cost savings, freeing up resources to focus on its Cloudbreak pipeline with the potential to deliver revolutionary therapies. This strategic move has been well-received by investors, reflected in the significant surge in the company’s stock price.